CD80 anticorps

N° du produit ABIN7189412

L’anticorps anti-CD80 Polyclonal produit chez le Lapin a été validé pour ELISA et IHC. Il convient pour la détection de CD80 dans des échantillons provenant de Humain. }

Aperçu rapide pour CD80 anticorps (ABIN7189412)

Antigène: CD80

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp CD80 est non-conjugé

Application: ELISA, Immunohistochemistry (IHC)

Détail du produit anti-CD80 anticorps

Fonction: CD80 Antibody

Purification: The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen.

Immunogène: Synthetic peptide from Human protein at AA range: 100-160

Isotype: IgG

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: PBS, pH 7.4, containing 0.02 % sodium azide as Preservative and 50 % Glycerol.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Détails sur CD80

Antigène: CD80

Autre désignation: CD80

Sujet: Activation B7-1 antigen antibody, B lymphocyte activation antigen B7 antibody, B7 antibody, B7-1 antibody, B7-1 antigen antibody, B7.1 antibody, BB1 antibody, CD28 antigen ligand 1 antibody, CD28LG antibody, CD28LG1 antibody, CD80 antibody, CD80 antigen (CD28 antigen ligand 1, B7-1 antigen) antibody, CD80 antigen antibody, CD80 Molecule antibody, CD80_HUMAN antibody, Costimulatory factor CD80 antibody, costimulatory molecule variant IgV-CD80 antibody, CTLA-4 counter-receptor B7.1 antibody, LAB7 antibody, T-lymphocyte activation antigen CD80 antibody

UniProt: P33681

Pathways: TCR Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints